Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report report published on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating on the stock in a report on Wednesday, August 7th.

Minerva Neurosciences Trading Down 3.8 %

Shares of NERV stock opened at $2.55 on Wednesday. Minerva Neurosciences has a 12-month low of $2.26 and a 12-month high of $13.49. The business’s 50 day moving average is $3.14 and its two-hundred day moving average is $3.65. The company has a market capitalization of $17.83 million, a P/E ratio of -0.57 and a beta of 0.15.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.12). On average, research analysts predict that Minerva Neurosciences will post -1.89 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.